Date: 2024-08-30
Authors: Mark Lebwohl 1, Michael Bukhalo 2, Linda Stein Gold 3, Brad Glick 4, Mar Llamas-Velasco 5, Samuel Sanchez-Rivera 6, Anqi Pan 7, Tianyu Zhan 7, Leonidas Drogaris 7, Kevin Douglas 7, Greg St John 7, Ramon Espaillat 7, Robert Bissonnette 8
Category: Psoriasis
Background: In plaque psoriasis, palmoplantar areas are more difficult to treat.
Objective: Evaluate the safety and efficacy of risankizumab (RZB) versus placebo (PBO) for the treatment of palmoplantar psoriasis.